Found: 52
Select item for more details and to access through your institution.
Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
- Published in:
- Journal of Hematology & Oncology, 2018, v. 11, p. 1, doi. 10.1186/s13045-018-0575-7
- By:
- Publication type:
- Article
Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.
- Published in:
- Journal of Clinical Investigation, 2014, v. 124, n. 7, p. 3121, doi. 10.1172/JCI74556
- By:
- Publication type:
- Article
Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect<sup>®</sup> MM Registry.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 1, p. 93, doi. 10.1111/bjh.17131
- By:
- Publication type:
- Article
Development of a prognostic model for overall survival in multiple myeloma using the Connect<sup>®</sup> MM Patient Registry.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 5, p. 602, doi. 10.1111/bjh.16139
- By:
- Publication type:
- Article
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
- Published in:
- Journal of Clinical Apheresis, 2015, v. 30, n. 3, p. 176, doi. 10.1002/jca.21360
- By:
- Publication type:
- Article
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 1, p. 140, doi. 10.1002/ajh.26596
- By:
- Publication type:
- Article
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 4, p. 418, doi. 10.1002/ajh.26083
- By:
- Publication type:
- Article
Multiple Myeloma: An Update on Diagnostic and Treatment Strategies.
- Published in:
- Journal of Managed Care Medicine, 2011, v. 14, n. 2, p. 34
- By:
- Publication type:
- Article
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 2, p. 369, doi. 10.1007/s00277-022-05056-7
- By:
- Publication type:
- Article
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Connect MM Registry as a national reference for United States multiple myeloma patients.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 1, p. 35, doi. 10.1002/cam4.2656
- By:
- Publication type:
- Article
The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma cells without a t(11;14) translocation.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 7, p. 3257, doi. 10.1002/cam4.1543
- By:
- Publication type:
- Article
Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality.
- Published in:
- PLoS ONE, 2020, v. 15, n. 9, p. 1, doi. 10.1371/journal.pone.0238824
- By:
- Publication type:
- Article
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 11, p. 2408
- By:
- Publication type:
- Article
Dyshematopoiesis in combined immune deficiency with congenital neutropenia.
- Published in:
- American Journal of Hematology, 1994, v. 45, n. 1, p. 63, doi. 10.1002/ajh.2830450110
- By:
- Publication type:
- Article
The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect® MM Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 10, p. e336, doi. 10.1016/j.clml.2024.05.021
- By:
- Publication type:
- Article
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 2, p. 112, doi. 10.1016/j.clml.2022.11.008
- By:
- Publication type:
- Article
Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 3, p. 149, doi. 10.1016/j.clml.2021.08.007
- By:
- Publication type:
- Article
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 11, p. 775, doi. 10.1016/j.clml.2021.07.029
- By:
- Publication type:
- Article
P-136: Health-related quality of life (HRQL) among real-world Ide-Cel–eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect® MM registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S109, doi. 10.1016/S2152-2650(21)02263-1
- By:
- Publication type:
- Article
OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02100-5
- By:
- Publication type:
- Article
MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S439, doi. 10.1016/S2152-2650(21)01978-9
- By:
- Publication type:
- Article
MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S439, doi. 10.1016/S2152-2650(21)01979-0
- By:
- Publication type:
- Article
Poster: MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01579-2
- By:
- Publication type:
- Article
Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01578-0
- By:
- Publication type:
- Article
Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effect of t(11;14) on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e74, doi. 10.1016/j.clml.2019.09.118
- By:
- Publication type:
- Article
Frequency of and Associations Amongst Baseline Cytogenetics in Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e75, doi. 10.1016/j.clml.2019.09.119
- By:
- Publication type:
- Article
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e55, doi. 10.1016/j.clml.2019.09.084
- By:
- Publication type:
- Article
A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e31, doi. 10.1016/j.clml.2019.09.046
- By:
- Publication type:
- Article
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).
- Published in:
- 2018
- By:
- Publication type:
- journal article
Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e27, doi. 10.1016/j.clml.2017.03.046
- By:
- Publication type:
- Article
Treatment Patterns From 2009-2015 in Patients With Newly Diagnosed Multiple Myeloma in the United States: A Report From the Connect® MM Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e20, doi. 10.1016/j.clml.2017.03.035
- By:
- Publication type:
- Article
Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e89, doi. 10.1016/j.clml.2017.03.160
- By:
- Publication type:
- Article
Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e5, doi. 10.1016/j.clml.2017.03.009
- By:
- Publication type:
- Article
Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial.
- Published in:
- Clinical Infectious Diseases, 2016, v. 63, n. 8, p. 999, doi. 10.1093/cid/ciw451
- By:
- Publication type:
- Article
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect<sup>®</sup> MM Registry.
- Published in:
- 2021
- By:
- Publication type:
- Letter
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Recognition of early mortality in multiple myeloma by a prediction matrix.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 9, p. 915, doi. 10.1002/ajh.24796
- By:
- Publication type:
- Article
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
- Published in:
- Journal of Hematology & Oncology, 2016, v. 9, p. 1, doi. 10.1186/s13045-016-0301-2
- By:
- Publication type:
- Article
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Morphologic Examination of Sequential Bone Marrow Biopsies after Nonmyeloablative Stem Cell Transplantation Complements Molecular Studies of Donor Engraftment.
- Published in:
- Archives of Pathology & Laboratory Medicine, 2006, v. 130, n. 10, p. 1479, doi. 10.5858/2006-130-1479-meosbm
- By:
- Publication type:
- Article
Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment.
- Published in:
- EJHaem, 2022, v. 3, n. 4, p. 1270, doi. 10.1002/jha2.572
- By:
- Publication type:
- Article